Table 1.
Patient demographics and baseline characteristics (N = 93)
| Characteristic | Value$ |
|---|---|
| Age, years | 40.0 ± 12.4 |
| Sex, no. (%) | |
| Male | 50 (53.8) |
| Female | 43 (46.2) |
| BM blasts, % | 0.4 ± 0.3 |
| HB, g/dL | 91.0 ± 25.3 |
| WBC, × 109/L | 9.2 ± 15.9 |
| PLT, × 109/L | 69.5 ± 66.4 |
| ECOG PS, no. (%) | |
| 0 | 34 (36.6) |
| 1 | 42 (45.2) |
| 2 | 16 (17.2) |
| 3 | 1 (1.1) |
| FAB classification, no. (%) | |
| M0 | 2 (2.2) |
| M1 | 3 (3.2) |
| M2 | 49 (52.7) |
| M4 | 14 (15.1) |
| M5 | 24 (25.8) |
| M6 | 1 (1.1) |
| Diagnosis, no. (%) | |
| Refractory | 37 (39.8) |
| Early relapse | 38 (40.9) |
| Late relapse | 18 (19.4) |
| Antecedent hematologic disorders, no. (%) | |
| Myelodysplastic syndromes | 3 (3.2) |
| Aplastic anemia | 1 (1.1) |
| Prior therapies, no. (%) | |
| 0–5 | 52 (55.9) |
| 6–10 | 28 (30.1) |
| ≥ 11 | 13 (14.0) |
| Prior therapy, no. (%) | |
| Prior epigenetic agents | 17 (18.3) |
| Prior allogeneic stem cell transplant | 2 (2.2) |
| Karyotype, no. (%) | |
| Normal karyotype | 54 (58.1) |
| Complex karyotype# | 9 (9.7) |
| T (8; 21) | 13 (14.0) |
| Mutation counts, no. (%)* | |
| 0 | 12 (13.6) |
| 1 | 20 (22.7) |
| 2 | 22 (25.0) |
| 3 | 19 (21.6) |
| 4 | 12 (13.6) |
| 5 | 3 (3.4) |
Abbreviations: BM bone marrow, HB hemoglobin, WBC white blood cell count, PLT platelets, ECOG PS Eastern Cooperative Oncology Group performance score, FAB French-American-British, CEBPA-dm CEPBA double mutation
$Descriptive statistics were presented as the mean ± standard deviation (mean ± SD) for continuous data and as numbers and percentages for dichotomous/categorical data
*Measured in 88 patients who underwent gene mutation detection
#Complex karyotype was defined as ≥ 3 clonal chromosomal abnormalities